References
- Adviento, B., Corbin, I. L., Widjaja, F., Desachy, G., Enrique, N., Rosser, T., Risi, S., Marco, E. J., Hendren, R. L., Bearden, C. E., Rauen, K. A., & Weiss, L. A. (2014). Autism traits in the RASopathies. Journal of Medical Genetics, 51(1), 10–20. https://doi.org/https://doi.org/10.1136/jmedgenet-2013-101951
- Antshel, K. M., & Russo, N. (2019). Autism spectrum disorders and ADHD: Overlapping phenomenology, diagnostic issues, and treatment considerations. Current Psychiatry Reports, 21(5), 34. https://doi.org/https://doi.org/10.1007/s11920-019-1020-5
- Baribeau, D. A., Doyle-Thomas, K. A. R., Dupuis, A., Iaboni, A., Crosbie, J., McGinn, H., Arnold, P. D., Brian, J., Kushki, A., Nicolson, R., Schachar, R. J., Soreni, N., Szatmari, P., & Anagnostou, E. (2015). Examining and comparing social perception abilities across childhood-onset neurodevelopmental disorders. Journal of the American Academy of Child & Adolescent Psychiatry, 54(6), 479–486. https://doi.org/https://doi.org/10.1016/j.jaac.2015.03.016
- Berument, S. K., Rutter, M., Lord, C., Pickles, A., & Bailey, A. (1999). Autism screening questionnaire: Diagnostic validity. The British Journal of Psychiatry: The Journal of Mental Science, 175, 444–451. https://doi.org/https://doi.org/10.1192/bjp.175.5.444
- Bloemen, A. J. P., Oldehinkel, A. J., Laceulle, O. M., Ormel, J., Rommelse, N. N. J., & Hartman, C. A. (2018). The association between executive functioning and psychopathology: General or specific? Psychological Medicine, 48(11), 1787–1794. https://doi.org/https://doi.org/10.1017/S0033291717003269
- Brei, N. G., Klein-Tasman, B. P., Schwarz, G. N., & Casnar, C. L. (2014). Language in young children with neurofibromatosis-1: Relations to functional communication, attention, and social functioning. Research in Developmental Disabilities, 35(10), 2495–2504. https://doi.org/https://doi.org/10.1016/j.ridd.2014.06.016
- Chabernaud, C., Sirinelli, D., Barbier, C., Cottier, J.-P., Sembely, C., Giraudeau, B., Deseille-Turlotte, G., Lorette, G., Barthez, M.-A., & Castelnau, P. (2009). Thalamo-striatal T2-weighted hyperintensities (unidentified bright objects) correlate with cognitive impairments in neurofibromatosis type 1 during childhood. Developmental Neuropsychology, 34(6), 736–748. https://doi.org/https://doi.org/10.1080/87565640903265137
- Chandler, S., Charman, T., Baird, G., Simonoff, E., Loucas, T., Meldrum, D., Scott, M., & Pickles, A. (2007). Validation of the social communication questionnaire in a population cohort of children with autism spectrum disorders. Journal of the American Academy of Child and Adolescent Psychiatry, 46(10), 1324–1332. https://doi.org/https://doi.org/10.1097/chi.0b013e31812f7d8d
- Cohen, R., Steinberg, T., Kornreich, L., Aharoni, S., Halevy, A., & Shuper, A. (2015). Brain imaging findings and social/emotional problems in Israeli children with neurofibromatosis type 1. European Journal of Pediatrics, 174(2), 199–203. https://doi.org/https://doi.org/10.1007/s00431-014-2366-7
- de Boer, A., & Pijl, S. J. (2016). The acceptance and rejection of peers with ADHD and ASD in general secondary education. The Journal of Educational Research, 109(3), 325–332. https://doi.org/https://doi.org/10.1080/00220671.2014.958812
- Fernell, E., Eriksson, M. A., & Gillberg, C. (2013). Early diagnosis of autism and impact on prognosis: A narrative review. Clinical Epidemiology, 5, 33–43. https://doi.org/https://doi.org/10.2147/CLEP.S41714
- Garg, S., Brooks, A., Burns, A., Burkitt-Wright, E., Kerr, B., Huson, S., Emsley, R., & Green, J. (2017). Autism spectrum disorder and other neurobehavioural comorbidities in rare disorders of the Ras/MAPK pathway. Developmental Medicine and Child Neurology, 59(5), 544–549. https://doi.org/https://doi.org/10.1111/dmcn.13394
- Garg, S., Green, J., Leadbitter, K., Emsley, R., Lehtonen, A., Evans, D. G., & Huson, S. M. (2013). Neurofibromatosis type 1 and autism spectrum disorder. PEDIATRICS, 132(6), e1642-8–e1648. https://doi.org/https://doi.org/10.1542/peds.2013-1868
- Garg, S., Lehtonen, A., Huson, S. M., Emsley, R., Trump, D., Evans, D. G., & Green, J. (2013). Autism and other psychiatric comorbidity in neurofibromatosis type 1: Evidence from a population-based study. Developmental Medicine and Child Neurology, 55(2), 139–145. https://doi.org/https://doi.org/10.1111/dmcn.12043
- Garg, S., Plasschaert, E., Descheemaeker, M.-J., Huson, S., Borghgraef, M., Vogels, A., Evans, D. G., Legius, E., & Green, J. (2015). Autism spectrum disorder profile in neurofibromatosis type I. Journal of Autism and Developmental Disorders, 45(6), 1649–1657. https://doi.org/https://doi.org/10.1007/s10803-014-2321-5
- Heimgärtner, M., Granström, S., Haas-Lude, K., Leark, R. A., Mautner, V. F., & Lidzba, K. (2019). Attention deficit predicts intellectual functioning in children with neurofibromatosis type 1. International Journal of Pediatrics, 2019, 1–10. eCollection 2019. https://doi.org/https://doi.org/10.1155/2019/9493837
- Hiatt, K. K., Ingram, D. A., Zhang, Y., Bollag, G., & Clapp, D. W. (2001). Neurofibromin GTPase-activating protein-related domains restore normal growth in Nf1–/– cells. The Journal of Biological Chemistry, 276(10), 7240–7245. https://doi.org/https://doi.org/10.1074/jbc.M009202200
- Li, W., Cui, Y., Kushner, S. A., Brown, R. A. M., Jentsch, J. D., Frankland, P. W., Cannon, T. D., & Silva, A. J. (2005). The HMG-CoA reductase inhibitor lovastatin reverses the learning and attention deficits in a mouse model of neurofibromatosis type 1. Current Biology: CB, 15(21), 1961–1967. https://doi.org/https://doi.org/10.1016/j.cub.2005.09.043
- Loomes, R., Hull, L., & Mandy, W. (2017 ). What Is the male-to-female ratio in autism spectrum disorder? A systematic review and meta-analysis. Journal of the American Academy of Child and Adolescent Psychiatry, 56(6), 466–474. https://doi.org/https://doi.org/10.1016/j.jaac.2017.03.013
- Miles, J. H. (2011). Autism spectrum disorders-a genetics review. Genetics in Medicine: Official Journal of the American College of Medical Genetics, 13(4), 278–294. https://doi.org/https://doi.org/10.1097/GIM.0b013e3181ff67ba
- Miodovnik, A., Harstad, E., Sideridis, G., & Huntington, N. (2015). Timing of the diagnosis of attention-deficit/hyperactivity disorder and autism spectrum disorder. Pediatrics, 136(4), e830–e837. https://doi.org/https://doi.org/10.1542/peds.2015-1502
- Morris, S. M., Acosta, M. T., Garg, S., Green, J., Huson, S., Legius, E., North, K. N., Payne, J. M., Plasschaert, E., Frazier, T. W., Weiss, L. A., Zhang, Y., Gutmann, D. H., & Constantino, J. N. (2016). Disease burden and symptom structure of autism in neurofibromatosis type 1: A study of the International NF1-ASD Consortium Team (INFACT). JAMA Psychiatry, 73(12), 1276–1284. https://doi.org/https://doi.org/10.1001/jamapsychiatry.2016.2600
- National institutes. National institutes of health consensus development conference statement: (1988). Neurofibromatosis. Bethesda, MD, USA, july 13-15, 1987. Neurofibromatosis, 1(3), 172–178.
- Neurofibromatosis. (1988). Conference statement. National Institutes of Health Consensus Development Conference. Archives of Neurology. 45, 575–578.
- North, K., Joy, P., Yuille, D., Cocks, N., Mobbs, E., Hutchins, P., McHugh, K., & de Silva, M. (1994). Specific learning disability in children with neurofibromatosis type 1: Significance of MRI abnormalities. Neurology, 44(5), 878–883. https://doi.org/https://doi.org/10.1212/wnl.44.5.878
- Ozonoff, S. (1999). Cognitive impairment in neurofibromatosis type 1. American Journal of Medical Genetics, 89(1), 45–52. https://doi.org/https://doi.org/10.1002/(SICI)1096-8628(19990326)89:1<45::AID-AJMG9>3.0.CO;2-J
- Payne, J. M. (2013). Autism spectrum disorder symptomatology in children with neurofibromatosis type 1. Developmental Medicine and Child Neurology, 55(2), 100–101. https://doi.org/https://doi.org/10.1111/dmcn.12075
- Plasschaert, E., Descheemaeker, M. J., Van Eylen, L., Noens, I., Steyaert, J., & Legius, E. (2015). Prevalence of autism spectrum disorder symptoms in children with neurofibromatosis type 1. American Journal of Medical Genetics. Part B, Neuropsychiatric Genetics: The Official Publication of the International Society of Psychiatric Genetics, 168B(1), 72–80. https://doi.org/https://doi.org/10.1002/ajmg.b.32280
- Rauen, K. A. (2013). The RASopathies. Annual review of genomics and human genetics, 14, 355–369. https://doi.org/https://doi.org/10.1146/annurev-genom-091212-153523
- Richards, C., Jones, C., Groves, L., Moss, J., & Oliver, C. (2015). Prevalence of autism spectrum disorder phenomenology in genetic disorders: A systematic review and meta-analysis. The Lancet. Psychiatry, 2(10), 909–916. https://doi.org/https://doi.org/10.1016/S2215-0366(15)00376-4
- Sprenger, L., Bühler, E., Poustka, L., Bach, C., Heinzel-Gutenbrunner, M., Kamp-Becker, I., & Bachmann, C. (2013). Impact of ADHD symptoms on autism spectrum disorder symptom severity. Research in Developmental Disabilities, 34(10), 3545–3552. https://doi.org/https://doi.org/10.1016/j.ridd.2013.07.028
- Walsh, K. S., Vélez, J. I., Kardel, P. G., Imas, D. M., Muenke, M., Packer, R. J., Castellanos, F. X., & Acosta, M. T. (2013). Symptomatology of autism spectrum disorder in a population with neurofibromatosis type 1. Developmental Medicine and Child Neurology, 55(2), 131–138. https://doi.org/https://doi.org/10.1111/dmcn.12038
- Williams, V. C., Lucas, J., Babcock, M. A., Gutmann, D. H., Korf, B., & Maria, B. L. (2009). Neurofibromatosis type 1 revisited. Pediatrics, 123(1), 124–133. https://doi.org/https://doi.org/10.1542/peds.2007-3204
- Wolraich, M. L., Bard, D. E., Neas, B., Doffing, M., & Beck, L. (2013). The psychometric properties of the Vanderbilt attention-deficit hyperactivity disorder diagnostic teacher rating scale in a community population. J Dev Behav Pediatr, 34(2), 83–93.